Navigation Links
Mylan Launches Generic Version of Cyklokapron® Injection
Date:12/2/2011

PITTSBURGH, Dec. 2, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials. This product is the generic version of Pharmacia & Upjohn's Cyklokapron® Injection, which is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage during and following oral surgery.

Tranexamic Acid Injection had U.S. sales of approximately $17 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 165 ANDAs pending FDA approval representing $99.4 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
2. Mylan Launches Generic Version of Caduet® Tablets
3. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
4. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
5. Mylan Receives Approval for Generic Version of Zinecard® for Injection
6. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
7. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
8. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
9. Mylan to Acquire Pfizer Respiratory Delivery Platform
10. Mylan Receives Approval for Generic Version of MS Contin® Tablets
11. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... FLINT, Mich. , April 28, 2016 /PRNewswire/ ... transaction . Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... it has signed a definitive agreement to acquire ... Advanced Specialty Pharmacy ("TNH"), a leading specialty pharmacy ... Van Nuys, California . In 2015, ...
(Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
Breaking Medicine Technology:
(Date:4/30/2016)... Jamaica (PRWEB) , ... April 30, 2016 , ... ... and Duane Boise, President and CEO of EMED, today signed a multifaceted agreement ... , EMED and the Northern Caribbean University Department of Natural and Applied Sciences, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... April 4th, 2016 questioned the use of the HyProCure sinus tarsi implant. ... controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to ...
(Date:4/30/2016)... ... ... a challenge for all of us, but there are things we can do to improve the ... is showing more and more that there are simple, yet important steps that can be taken ... priorities Dr. Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/30/2016)... ... , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of Indianapolis to ... the care of Maximized Living doctors at the London Olympics in 2012, U.S. wrestlers ... sending the largest contingent of elite chiropractors to Rio to support and care for ...
(Date:4/29/2016)... FL (PRWEB) , ... April 30, 2016 , ... ... and engineer of patented products, announces the Pick Up Springboard, an automotive invention ... and Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):